Sino-US biotech firm MicuRx Pharmaceuticals Inc. (SHA: 688373) has filed a lawsuit against US-based Medpace, Inc. in the Western Division of the United States District Court for the Southern District of Ohio. The suit accuses Medpace of violating contractual obligations and seeks compensation for losses and expenses, including interest up to the judgment date. MicuRx also requests additional remedies deemed fair by the court.
Background of the Dispute
The legal action stems from a Master Services Agreement signed on January 5, 2022, under which Medpace was engaged as a Contract Research Organization (CRO) to manage MicuRx’s global, multi-center Phase III study for MRX-4 combined with contezolid (MRX-I). However, Medpace failed to meet agreed goals. MicuRx terminated Task Order 1 in December 2023 and requested data return. In early 2024, Medpace sought to terminate Task Order 2 but did not transfer data, infringing MicuRx’s rights.
Mediation and Data Return
MicuRx applied for a temporary court order to retrieve the data. A mediation agreement was reached in November 2024, with MicuRx providing the required deposit and Medpace returning the data as stipulated.
Ongoing Litigation
The parties remain deadlocked on other claims. MicuRx’s lawsuit, confirmed by the court on February 24, 2025, seeks compensation for losses. The case has not yet been heard.
Impact on Clinical Trials
MicuRx stated the lawsuit will not affect its Phase III study for MRX-4/MRX-I, having replaced the CRO in Q1 2024. The completed Phase III study in China is also unaffected.-Fineline Info & Tech
